Back to Trades
Other4
Avidity Biosciences, Inc.
RNAM
Total Value
$2.0M
Company Information
- Company Name
- Avidity Biosciences, Inc.
- Ticker Symbol
- RNAM
- CIK
- 0001599901
Insider Information
- Name
- BOESS CARSTEN
- Role
- Insider
- Location
- SAN DIEGO, CA
Filing Details
- Filing Date
- Feb 27, 2026
- Transaction Date
- Feb 27, 2026
- Accession Number
- 0001193125-26-082132
- Form Type
- 4
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Feb 27, 2026 | Common Stock | 6,692 | — | Disposition | — |
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Feb 27, 2026 | Derivative | 10,034 | $33.62 | Disposition | $337.3K |
| Feb 27, 2026 | Derivative | 13,489 | $39.96 | Disposition | $539.0K |
| Feb 27, 2026 | Derivative | 22,000 | $12.48 | Disposition | $274.6K |
| Feb 27, 2026 | Derivative | 22,000 | $12.03 | Disposition | $264.7K |
| Feb 27, 2026 | Derivative | 15,000 | $26.09 | Disposition | $391.4K |
| Feb 27, 2026 | Derivative | 20,858 | $8.82 | Disposition | $184.0K |
Footnotes
- (F1)The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer.
- (F2)The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.